Intrinsic Value of S&P & Nasdaq Contact Us

Galecto, Inc. GLTO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$43.67
+64%

Galecto, Inc. (GLTO) generated $566K in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $566K.

Cash conversion ratio was -0x, suggesting some earnings are non-cash.

Criteria supported by this page:

  • HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
  • MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
  • INCOME (?/100) — Cash conversion ratio was -0x suggests some earnings are non-cash items

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
53/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
→ Valuation
FUTURE
73/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
28/100
Proven by this page
GROWTH
15/100
→ Income
INCOME
N/A
No coverage
Galecto, Inc. Cash Flow History
Metric TTM Q4 FY2025 Q3 FY2025 Q2 FY2025 Q1 FY2025
Operating Cash Flow $-6.73M$566K$-2.62M$-2.24M$-2.44M
Capital Expenditure $0.00$0.00$0.00$0.00$0.00
Free Cash Flow $-6.73M$566K$-2.62M$-2.24M$-2.44M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message